1887

Abstract

Signal transducer and activator of transcription 3 (STAT3) deficiency is a rare primary immunodeficiency associated with increased susceptibility to bacterial and fungal infections, notably pulmonary aspergillosis.

We describe the emergence of azole-resistant infections in STAT3-deficient patients.

During a retrospective study of 13 pulmonary aspergillosis cases in STAT3-deficient patients conducted in France, we identified patients infected with azole-resistant isolates.

Two out of the 13 STAT3-deficient patients with aspergillosis had azole-resistant infection, indicating an unexpectedly high prevalence of resistance. The first patient with STAT3 deficiency presented several flares of allergic bronchopulmonary aspergillosis-like episodes. He was chronically infected with two azole-resistant isolates (TR/L98). Despite prolonged antifungal treatment, including caspofungin and amphotericin B, the patient was not able to clear the azole-resistant . The second patient had chronic cavitary pulmonary aspergillosis (CCPA). The isolate was initially azole susceptible but harboured three F46Y, M172V and E427K point mutations. Despite prolonged antifungal therapies, lesions worsened and the isolate became resistant to all azoles. Surgery and caspofungin treatments were then required to cure CCPA. Resistance was probably acquired from the environment (TR/L98) in the first case whereas resistance developed under antifungal treatments in the second case. These infections required long-term antifungal treatments and surgery.

The emergence of azole-resistant infections in STAT3-deficiency dramatically impacts both curative and prophylactic antifungal strategies. Physicians following patients with primary immune-deficiencies should be aware of this emerging problem as it complicates management of the patient.

Funding
This study was supported by the:
  • Fanny Lanternier , CEREDIH , (Award 2017)
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001200
2020-05-27
2020-07-02
Loading full text...

Full text loading...

/deliver/fulltext/jmm/69/6/844.html?itemId=/content/journal/jmm/10.1099/jmm.0.001200&mimeType=html&fmt=ahah

References

  1. Chandesris M-O, Melki I, Natividad A, Puel A, Fieschi C et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine 2012; 91:e1–19 [CrossRef][PubMed]
    [Google Scholar]
  2. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G et al. Stat3 mutations in the hyper-IgE syndrome. N Engl J Med 2007; 357:1608–1619 [CrossRef][PubMed]
    [Google Scholar]
  3. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H et al. Dominant-Negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007; 448:1058–1062 [CrossRef][PubMed]
    [Google Scholar]
  4. Vinh DC, Sugui JA, Hsu AP, Freeman AF, Holland SM. Invasive fungal disease in autosomal-dominant hyper-IgE syndrome. J Allergy Clin Immunol 2010; 125:1389–1390 [CrossRef][PubMed]
    [Google Scholar]
  5. Duréault A, Tcherakian C, Poiree S, Catherinot E, Danion F et al. Spectrum of pulmonary aspergillosis in hyper-IgE syndrome with autosomal-dominant STAT3 deficiency. J Allergy Clin Immunol Pract 2019; 7:1986–1995 [CrossRef][PubMed]
    [Google Scholar]
  6. Lestrade PP, Bentvelsen RG, Schauwvlieghe A, Schalekamp S, van der Velden W et al. Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study. Clin Infect Dis Off Publ Infect Dis Soc Am 2018
    [Google Scholar]
  7. Resendiz-Sharpe A, Mercier T, Lestrade PPA, van der Beek MT, von dem Borne PA et al. Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients. J Antimicrob Chemother 2019; 74:2759–2766 [CrossRef][PubMed]
    [Google Scholar]
  8. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing Eucast technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 2008; 14:982–984 [CrossRef][PubMed]
    [Google Scholar]
  9. Garcia-Hermoso D, Valenzuela-Lopez N, Rivero-Menendez O, Alastruey-Izquierdo A, Guarro J et al. Diversity of coelomycetous fungi in human infections: a 10-y experience of two European reference centres. Fungal Biol 2019; 123:341–349 [CrossRef][PubMed]
    [Google Scholar]
  10. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus . Antimicrob Agents Chemother 2003; 47:1120–1124 [CrossRef][PubMed]
    [Google Scholar]
  11. Alanio A, Sitterlé E, Liance M, Farrugia C, Foulet F et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother 2011; 66:371–374 [CrossRef][PubMed]
    [Google Scholar]
  12. Bart-Delabesse E, Cordonnier C, Bretagne S. Usefulness of genotyping with microsatellite markers to investigate hospital-acquired invasive aspergillosis. J Hosp Infect 1999; 42:321–327 [CrossRef][PubMed]
    [Google Scholar]
  13. Burgel P-R, Baixench M-T, Amsellem M, Audureau E, Chapron J et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother 2012; 56:869–874 [CrossRef][PubMed]
    [Google Scholar]
  14. van der Linden JWM, Arendrup MC, Warris A, Lagrou K, Pelloux H et al. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus . Emerg Infect Dis 2015; 21:1041–1044 [CrossRef][PubMed]
    [Google Scholar]
  15. Verweij PE, Snelders E, Kema GHJ, Mellado E, Melchers WJG. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?. Lancet Infect Dis 2009; 9:789–795 [CrossRef][PubMed]
    [Google Scholar]
  16. Snelders E, Karawajczyk A, Schaftenaar G, Verweij PE, Melchers WJG. Azole resistance profile of amino acid changes in Aspergillus fumigatus cyp51A based on protein homology modeling. Antimicrob Agents Chemother 2010; 54:2425–2430 [CrossRef][PubMed]
    [Google Scholar]
  17. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Substitutions at methionine 220 in the 14alpha-sterol demethylase (cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 2004; 48:2747–2750 [CrossRef][PubMed]
    [Google Scholar]
  18. Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis 2017; 17:e383–e392 [CrossRef][PubMed]
    [Google Scholar]
  19. Rivero-Menendez O, Alastruey-Izquierdo A, Mellado E, Cuenca-Estrella M. Triazole resistance in Aspergillus spp.: a worldwide problem?. J Fungi 2016; 2:E2121 [CrossRef][PubMed]
    [Google Scholar]
  20. Alanio A, Cabaret O, Sitterlé E, Costa J-M, Brisse S et al. Azole preexposure affects the Aspergillus fumigatus population in patients. Antimicrob Agents Chemother 2012; 56:4948–4950 [CrossRef][PubMed]
    [Google Scholar]
  21. Duréault A, Tcherakian C, Poiree S, Catherinot EA. Aspergillus spp. Infections in STAT3 deficient patients: a nationwide study in France. 7th Advances Against Aspergillosis, Manchester, 2016, abstract n° 99.
  22. Eppinger TM, Greenberger PA, White DA, Brown AE, Cunningham-Rundles C. Sensitization to Aspergillus species in the congenital neutrophil disorders chronic granulomatous disease and hyper-IgE syndrome. J Allergy Clin Immunol 1999; 104:1265–1272 [CrossRef][PubMed]
    [Google Scholar]
  23. Arendrup MC, Mavridou E, Mortensen KL, Snelders E, Frimodt-Møller N et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 2010; 5:e10080 [CrossRef][PubMed]
    [Google Scholar]
  24. Verweij PE, Zhang J, Debets AJM, Meis JF, van de Veerdonk FL et al. In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management. Lancet Infect Dis 2016; 16:e251–e260 [CrossRef][PubMed]
    [Google Scholar]
  25. Tashiro M, Izumikawa K, Hirano K, Ide S, Mihara T et al. Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus. Antimicrob Agents Chemother 2012; 56:4870–4875 [CrossRef][PubMed]
    [Google Scholar]
  26. Zhang J, Debets AJM, Verweij PE, Melchers WJG, Zwaan BJ et al. Asexual sporulation facilitates adaptation: the emergence of azole resistance in Aspergillus fumigatus. Evolution 2015; 69:2573–2586 [CrossRef][PubMed]
    [Google Scholar]
  27. Kida H, Mucenski ML, Thitoff AR, Le Cras TD, Park K-S et al. GP130-STAT3 regulates epithelial cell migration and is required for repair of the bronchiolar epithelium. Am J Pathol 2008; 172:1542–1554 [CrossRef][PubMed]
    [Google Scholar]
  28. Matsuzaki Y, Xu Y, Ikegami M, Besnard V, Park K-S et al. Stat3 is required for cytoprotection of the respiratory epithelium during adenoviral infection. J Immunol 2006; 177:527–537 [CrossRef][PubMed]
    [Google Scholar]
  29. Odio CD, Milligan KL, McGowan K, Rudman Spergel AK, Bishop R et al. Endemic mycoses in patients with STAT3-mutated hyper-IgE (job) syndrome. J Allergy Clin Immunol 2015; 136:1411–1413 [CrossRef][PubMed]
    [Google Scholar]
  30. Shi M, Lu S, Li J, Cai W, Zhang J et al. Cutaneous fusariosis caused by Fusarium lichenicola in a child with hyper-immunoglobulin E syndrome. J Dermatol 2019
    [Google Scholar]
  31. Freeman AF, Davis J, Anderson VL, Barson W, Darnell DN et al. Pneumocystis jiroveci infection in patients with hyper-immunoglobulin E syndrome. Pediatrics 2006; 118:e1271–e1275 [CrossRef][PubMed]
    [Google Scholar]
  32. Hodiamont CJ, Dolman KM, Ten Berge IJM, Melchers WJG, Verweij PE et al. Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol 2009; 47:217–220 [CrossRef][PubMed]
    [Google Scholar]
  33. Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 2016; 127:3154–3164 [CrossRef][PubMed]
    [Google Scholar]
  34. Freeman AF, Renner ED, Henderson C, Langenbeck A, Olivier KN et al. Lung parenchyma surgery in autosomal dominant hyper-IgE syndrome. J Clin Immunol 2013; 33:896–902 [CrossRef][PubMed]
    [Google Scholar]
  35. Aguilar C, Malphettes M, Donadieu J, Chandesris O, Coignard-Biehler H et al. Prevention of infections during primary immunodeficiency. Clin Infect Dis 2014; 59:1462–1470 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001200
Loading
/content/journal/jmm/10.1099/jmm.0.001200
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error